drugset / Trial / NCT00625560
Continuing Lamivudine vs Switching to Entecavir in Patients With Detectable HBV DNA
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a randomized, open-labelled, prospective 96-week study comparing the antiviral efficacy and safety of switching to entecavir 1 mg QD from lamivudine versus maintaining lamivudine 100 mg QD treatment in HBV-infected subjects currently receiving lamivudine monotherapy.
Timeline
- Start
- 2008-02
- Primary completion
- 2009-11
- Completion
- 2010-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Entecavir | Small molecule | 1 mg | — |
| Comparator | Lamivudine | Other / unclassified | 100 mg | — |